Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Teva Asks FDA Not to Approve New MS Drugs Till Advisers Evaluate Safety

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/09/2013 | 09:09pm CEST
   By Peter Loftus 
 

Teva Pharmaceutical Industries Ltd. (>> Teva Pharmaceutical Industries Ltd (ADR)), which sells the blockbuster multiple-sclerosis drug Copaxone, has asked the U.S. Food and Drug Administration not to approve any new MS drugs until their safety risks have been evaluated by outside advisers.

Teva's petition is aimed at Biogen Idec Inc. (>> Biogen Idec Inc.), which expects an FDA decision by late March on Biogen's application to market a new MS treatment, known as BG-12, an orally administered pill that analysts expect will be a formidable competitor to the injected Copaxone.

In a Dec. 31 citizen petition to the FDA, Teva asked the agency not to approve any new MS drugs until the agency refers them to an advisory committee for evaluation. Advisory committees sometimes review new drug applications to provide guidance to the agency.

Teva said it was important for the agency to hear outside advisers' evaluations of any safety risks, in light of risks that have emerged after MS treatments were approved in recent years, including Biogen's own Tysabri MS treatment. Tysabri was removed from the market soon after its 2004 introduction after some recipients experienced a serious brain infection, and reintroduced in 2006 with a patient-monitoring plan.

Teva said in its petition that BG-12 "may be associated with other serious safety risks" including the potential risk for kidney-related problems.

Teva cited a publicly accessible website containing animal toxicology data suggesting that kidney changes were seen in animals after they received BG-12's active ingredient, dimethyl fumarate, in studies. The website stated that the relevance of these findings to humans isn't known, according to the Teva petition.

Biogen spokeswoman Kate Niazi-Sai said the company is confident in the clinical data supporting BG-12's safety and efficacy, and the regulatory review appears to be on track.

Results of a late-stage clinical trial of BG-12 published last year in the New England Journal of Medicine showed the incidence of kidney-related adverse events was similar between those receiving BG-12 and those on a placebo. There were no cases of kidney failure classified by researchers as serious adverse events, according to the article.

RBC Capital Markets analyst Shibani Malhotra, who reported the Teva citizen petition in a research note earlier Wednesday, said it may not pose a big obstacle for BG-12's approval because a similar drug has been available as a psoriasis treatment in Europe, and serious safety issues haven't emerged.

RBC analyst Michael Yee said he still expects the FDA to approve BG-12 by the targeted action date in late March.

On Monday at the J.P. Morgan Healthcare conference in San Francisco, Biogen Chief Executive George Scangos defended the experimental MS pill. He acknowledged there has been some chatter about BG-12 safety, but chalked this up to competitors marketing against the product.

"We're very confident in the safety," he said. "I kind of take it as a compliment that the competition is worried about BG-12."

Teva spokeswoman Denise Bradley said the petition was intended to bring to light important points "to protect the safety of patients." Teva wants to ensure "that appropriate safeguards are implemented to maintain an acceptable risk-benefit profile" for any new MS drug, she said.

FDA spokeswoman Sandy Walsh said the agency will review the petition.

--Jon Kamp contributed to this article.

-Write to Peter Loftus at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
03:36p TEVA PHARMACEUTICAL INDUSTRIES LIMIT : DEADLINE MONDAY: Levi & Korsinsky, LLP Re..
10/19 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : DEADLINE MONDAY: Lundin Law PC Announces ..
10/19 TEVA PHARMACEUTICAL INDUSTRIES : to Report Third Quarter 2017 Financial Results ..
10/19 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : The Law Offices of Vincent Wong Reminds I..
10/19 TEVA PHARMACEUTICAL INDUSTRIES : Announces Submission of Biologics License Appli..
10/19 TEVA PHARMACEUTICAL INDUSTRIES : to Highlight New Data in Multiple Sclerosis at ..
10/18 TEVA REMINDER DEADLINE ALERT : The Law Offices of Howard G. Smith Reminds Invest..
10/18 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : APPROACHING DEADLINE: Khang & Khang LLP A..
10/18 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : Levi & Korsinsky, LLP Reminds Shareholder..
10/17 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : DEADLINE ALERT: Lundin Law PC Announces a..
More news
News from SeekingAlpha
10:45a Debt-laden pharmas under pressure on Concordia's debt restructuring
10/19 J&J : Unattractive
10/18 TEVA BULLS ARE TOO EARLY : Debt Downgrade On The Way
10/18 YOUR DAILY PHARMA SCOOP : AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
10/18 HEALTHCARE DOGFIGHT : Owens & Minor Edges GlaxoSmithKline As Top Broker Pick For..
Financials ($)
Sales 2017 22 644 M
EBIT 2017 6 282 M
Net income 2017 -
Debt 2017 34 451 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 2,17x
EV / Sales 2018 2,06x
Capitalization 14 723 M
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 28,0 $
Spread / Average Target 92%
Managers
NameTitle
Kåre Schultz President & Chief Executive Officer
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Michael McClellan Chief Financial Officer
Michael R. Hayden Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED-62.38%14 891
JOHNSON & JOHNSON23.29%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER11.58%213 372
MERCK AND COMPANY7.88%173 214